{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:21:11Z","timestamp":1791937271636,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5U19AI090023"],"award-info":[{"award-number":["5U19AI090023"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.coi.2019.02.005","type":"journal-article","created":{"date-parts":[[2019,4,7]],"date-time":"2019-04-07T04:44:35Z","timestamp":1554612275000},"page":"25-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Understanding the immunology of the Zostavax shingles vaccine"],"prefix":"10.1016","volume":"59","author":[{"given":"Nicole L","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane S","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpit A","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bali","family":"Pulendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafi","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2019.02.005_bib0005","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1056\/NEJMcp1302674","article-title":"Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.coi.2019.02.005_bib0010","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/infdis\/166.Supplement_1.S35","article-title":"Cell-mediated immunity to varicella-zoster virus","volume":"166","author":"Arvin","year":"1992","journal-title":"J Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.coi.2019.02.005_bib0015","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1086\/522123","article-title":"Humoral and cellular immunity to varicella-zoster virus: an overview","volume":"197","author":"Arvin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_bib0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","article-title":"Varicella-zoster virus","volume":"9","author":"Arvin","year":"1996","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coi.2019.02.005_bib0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/iai.25.1.170-174.1979","article-title":"Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections","volume":"25","author":"Gershon","year":"1979","journal-title":"Infect Immun"},{"issue":"Suppl. 1","key":"10.1016\/j.coi.2019.02.005_bib0030","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S1386-6532(10)70004-4","article-title":"Prevention strategies for herpes zoster and post-herpetic neuralgia","volume":"48","author":"Levin","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.coi.2019.02.005_bib0035","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.coi.2019.02.005_bib0040","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_bib0045","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.coi.2019.02.005_bib0050","first-page":"1528","article-title":"Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.coi.2019.02.005_bib0055","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention","volume":"45","year":"1996","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.coi.2019.02.005_bib0060","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJM198405313102201","article-title":"Live attenuated varicella virus vaccine. Efficacy trial in healthy children","volume":"310","author":"Weibel","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2019.02.005_bib0065","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0264-410X(00)00297-8","article-title":"The postmarketing safety profile of varicella vaccine","volume":"19","author":"Sharrar","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2019.02.005_bib0070","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2019.02.005_bib0075","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1016\/j.vaccine.2017.11.013","article-title":"Herpes zoster vaccine live: a 10 year review of post-marketing safety experience","volume":"35","author":"Willis","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2019.02.005_bib0080","first-page":"1","article-title":"A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL)","author":"Popmihajlov","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coi.2019.02.005_bib0085","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1080\/21645515.2018.1456598","article-title":"Post-licensure safety surveillance of zoster vaccine live (Zostavax\u00ae) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015","volume":"14","author":"Miller","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coi.2019.02.005_bib0090","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/kwx245","article-title":"Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study","volume":"187","author":"Baxter","year":"2018","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.coi.2019.02.005_bib0095","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_bib0100","first-page":"9","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.coi.2019.02.005_bib0105","series-title":"Fields\u2019 Cirology","first-page":"2731","article-title":"Varicella-zoster virus","author":"Arvin","year":"2001"},{"key":"10.1016\/j.coi.2019.02.005_bib0110","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1056\/NEJM198204013061301","article-title":"Human leukocyte interferon for the treatment of varicella in children with cancer","volume":"306","author":"Arvin","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2019.02.005_bib0115","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1084\/jem.20040634","article-title":"Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha","volume":"200","author":"Ku","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2019.02.005_sbref0120","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.cell.2017.04.026","article-title":"Metabolic phenotypes of response to vaccination in humans","volume":"169","author":"Li","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.coi.2019.02.005_bib0125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ni.2789","article-title":"Molecular signatures of antibody responses derived from a systems biology study of five human vaccines","volume":"15","author":"Li","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2019.02.005_bib0130","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/ni.2067","article-title":"Systems biology of vaccination for seasonal influenza in humans","volume":"12","author":"Nakaya","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2019.02.005_bib0135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199302113280601","article-title":"Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. An investigation of cases in the United States. The Centers for Disease Control Idiopathic CD4+ T-lymphocytopenia Task Force","volume":"328","author":"Smith","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2019.02.005_bib0140","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/infdis\/jiu500","article-title":"Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection","volume":"211","author":"Schub","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_bib0145","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01024-8","article-title":"Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox","volume":"7","author":"Ogunjimi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2019.02.005_bib0150","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1086\/315347","article-title":"Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression","volume":"181","author":"Asanuma","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_bib0155","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/infdis\/jiv164","article-title":"Zoster vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus","volume":"212","author":"Laing","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_bib0160","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fimmu.2015.00553","article-title":"Effector and central memory poly-functional CD4(+) and CD8(+) T cells are boosted upon ZOSTAVAX\u00ae vaccination","volume":"6","author":"Sei","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2019.02.005_bib0165","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI121484","article-title":"Th1 memory differentiates recombinant from live herpes zoster vaccines","volume":"128","author":"Levin","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2019.02.005_sbref0170","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/infdis\/jiy420","article-title":"Impact of Zostavax vaccination on T-Cell accumulation and cutaneous gene expression in the skin of older humans after varicella zoster virus antigen-specific challenge","volume":"218","author":"Patel","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_bib0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004008","article-title":"Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV","volume":"10","author":"Chiu","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2019.02.005_bib0180","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/375828","article-title":"Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination","volume":"188","author":"Frey","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_bib0185","doi-asserted-by":"crossref","first-page":"7361","DOI":"10.1128\/JVI.02662-08","article-title":"Identification of varicella-zoster virus-specific CD8 T cells in patients after T-cell-depleted allogeneic stem cell transplantation","volume":"83","author":"van der Heiden","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2019.02.005_sbref0190","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/infdis\/jix653","article-title":"Varicella-zoster virus DNA in blood after administration of herpes zoster vaccine","volume":"217","author":"Levin","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_sbref0195","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy984","article-title":"Characterization of virus-specific immune response during varicella zoster virus encephalitis in a young adult","author":"Sullivan","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_bib0200","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa013441","article-title":"Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants","volume":"347","author":"Hata","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2019.02.005_bib0205","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1586\/14760584.2013.844651","article-title":"The role of VariZIG in pregnancy","volume":"12","author":"Bapat","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coi.2019.02.005_bib0210","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/QCO.0b013e328345d666","article-title":"Preventing varicella in children with malignancies: what is the evidence?","volume":"24","author":"Fisher","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_bib0215","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0022-3476(81)80697-X","article-title":"Prophylaxis of varicella in high-risk children: dose-response effect of zoster immune globulin","volume":"98","author":"Orenstein","year":"1981","journal-title":"J Pediatr"},{"key":"10.1016\/j.coi.2019.02.005_bib0220","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/infdis\/147.4.737","article-title":"Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella","volume":"147","author":"Zaia","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_sbref0225","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00269-18","article-title":"Breadth and functionality of varicella-zoster virus glycoprotein-specific antibodies identified after Zostavax vaccination in humans","volume":"92","author":"Sullivan","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2019.02.005_bib0230","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/(SICI)1096-9071(199709)53:1<63::AID-JMV11>3.0.CO;2-Y","article-title":"Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization","volume":"53","author":"Haumont","year":"1997","journal-title":"J Med Virol"},{"key":"10.1016\/j.coi.2019.02.005_bib0235","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/infdis\/162.1.627","article-title":"Antibodies to varicella-zoster virus glycoproteins I, II, and III in leukemic and healthy children","volume":"162","author":"LaRussa","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.005_bib0240","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1128\/JVI.02097-08","article-title":"Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H","volume":"83","author":"Akahori","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2019.02.005_bib0245","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/JVI.02561-12","article-title":"Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH\/gL complex and neutralizes VZV infection","volume":"87","author":"Birlea","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2019.02.005_bib0250","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1128\/jvi.52.1.55-62.1984","article-title":"Varicella-zoster viral glycoproteins analyzed with monoclonal antibodies","volume":"52","author":"Forghani","year":"1984","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2019.02.005_bib0255","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1128\/iai.40.1.381-388.1983","article-title":"Monoclonal antibodies against three major glycoproteins of varicella-zoster virus","volume":"40","author":"Grose","year":"1983","journal-title":"Infect Immun"},{"key":"10.1016\/j.coi.2019.02.005_bib0260","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1128\/jvi.52.1.293-297.1984","article-title":"Three major glycoprotein genes of varicella-zoster virus whose products have neutralization epitopes","volume":"52","author":"Keller","year":"1984","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2019.02.005_bib0265","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0042-6822(86)90124-8","article-title":"Neutralization epitope of varicella zoster virus on native viral glycoprotein gp118 (VZV glycoprotein gpIII)","volume":"149","author":"Montalvo","year":"1986","journal-title":"Virology"},{"key":"10.1016\/j.coi.2019.02.005_bib0270","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1006\/viro.1993.1543","article-title":"Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody","volume":"196","author":"Rodriguez","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.coi.2019.02.005_bib0275","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1128\/JVI.00435-11","article-title":"Neutralizing anti-gH antibody of varicella-zoster virus modulates distribution of gH and induces gene regulation, mimicking latency","volume":"85","author":"Shiraki","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2019.02.005_bib0280","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1099\/0022-1317-72-9-2065","article-title":"A human monoclonal antibody against varicella-zoster virus glycoprotein III","volume":"72","author":"Sugano","year":"1991","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coi.2019.02.005_bib0285","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/jmv.20838","article-title":"Isolation of therapeutic human monoclonal antibodies for varicella-zoster virus and the effect of light chains on the neutralizing activity","volume":"79","author":"Suzuki","year":"2007","journal-title":"J Med Virol"},{"key":"10.1016\/j.coi.2019.02.005_bib0290","doi-asserted-by":"crossref","first-page":"18412","DOI":"10.1073\/pnas.1111333108","article-title":"Structure-function analysis of varicella-zoster virus glycoprotein H identifies domain-specific roles for fusion and skin tropism","volume":"108","author":"Vleck","year":"2011","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791518301249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791518301249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:34:47Z","timestamp":1760603687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791518301249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":58,"alternative-id":["S0952791518301249"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2019.02.005","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the immunology of the Zostavax shingles vaccine","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2019.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}